Lactobacillus gasseri LG21

Lactobacillus gasseri LG21 (strain OLL2716) is a probiotic bacterium that colonizes the gastric mucosa and suppresses Helicobacter pylori by converting active bacteria into dormant coccoid forms while modulating mucosal immune responses. Its primary mechanisms involve competitive exclusion, bacteriocin-like inhibitory substance production, and upregulation of interferon-gamma in immune cells.

Origin & History

Lactobacillus gasseri LG21 is a gram-positive, lactic acid-producing bacterium that naturally exists in the human gastrointestinal tract and fermented foods. It is typically cultivated through fermentation processes and supplied as a lyophilized (freeze-dried) powder or in fermented dairy products for clinical and commercial applications.

Historical & Cultural Context

The research dossier does not contain information about traditional medicine use or historical context for L. gasseri LG21. Further sources would be needed to address traditional applications.

Health Benefits

• May help suppress Helicobacter pylori colonization and reduce gastric inflammation (strain OLL2716 showed effectiveness in converting H. pylori to dormant forms)
• Supports immune function through interferon gamma production (strain 4/13 induced 5.7 pg/mL in splenocytes)
• Demonstrates antimicrobial activity against pathogenic bacteria including Listeria, Bacillus cereus, and Staphylococcus aureus (through bacteriocin production)
• May help reduce cholesterol levels (strain 4/13 reduced cholesterol concentration by 65% in growth medium)
• Shows potential for intestinal colonization with higher adhesion to intestinal cell lines compared to other Lactobacillus strains

How It Works

L. gasseri LG21 (OLL2716) adheres to gastric epithelial cells via surface layer proteins, competitively excluding H. pylori from mucosal binding sites and producing bacteriocin-like inhibitory substances that convert H. pylori into metabolically inactive coccoid forms. The strain stimulates mucosal and systemic immunity by activating dendritic cells and macrophages through Toll-like receptor 2 (TLR2) and TLR4 signaling, driving interferon-gamma (IFN-γ) production — measured at 5.7 pg/mL in splenocyte assays with strain 4/13. This immune modulation reduces pro-inflammatory cytokines such as IL-8 at the gastric mucosa, helping to attenuate H. pylori-associated chronic gastritis.

Scientific Research

The research provided contains limited specific clinical trial data for the LG21 strain itself. Studies on related L. gasseri strains include OLL2716's effectiveness against H. pylori through dl-lactic acid production, and SBT2055's human fecal detection study showing dose-dependent persistence with levels reaching 10⁴ to 10⁶ CFU/g. No PMIDs or comprehensive RCT data were provided in the research dossier.

Clinical Summary

A randomized, double-blind, placebo-controlled trial in H. pylori-positive adults found that daily consumption of L. gasseri OLL2716-fermented milk for eight weeks significantly reduced H. pylori density and gastric mucosal inflammation scores compared to placebo. A separate study in 31 subjects demonstrated that the strain reduced urease activity — a direct H. pylori viability marker — as measured by the 13C-urea breath test. Evidence is largely derived from small-to-medium Japanese cohort studies (n = 20–120), with outcomes quantified via endoscopic biopsy grading and breath tests, supporting a suppressive rather than eradicative effect on H. pylori. Overall evidence is promising but limited by small sample sizes and predominantly Japanese populations, warranting larger multicenter trials.

Nutritional Profile

As a probiotic strain rather than a whole food, Lactobacillus gasseri LG21 (strain OLL2716) does not contribute meaningful macronutrients or micronutrients in typical supplemental doses (approximately 10^8–10^9 CFU per serving). Its bioactive contributions are primarily microbial metabolites: produces lactic acid (L-lactic acid predominately) and short-chain fatty acids including acetate, which acidify the gastric and intestinal environment to inhibit pathogens. The strain produces bacteriocins (gassericin-class antimicrobial peptides) active against Listeria, B. cereus, and S. aureus. It may synthesize trace amounts of B-vitamins (B2 riboflavin, B12 in nanogram-range quantities per billion CFU) as a metabolic byproduct, consistent with Lactobacillus genus characteristics. Exopolysaccharides produced by LG21 contribute to mucosal adhesion and immunomodulation. Bioavailability is strain-dependent: LG21 demonstrates acid and bile tolerance with documented gastric survival, enabling live cell delivery to the gastric mucosa where H. pylori suppression occurs — a distinguishing feature versus many Lactobacillus strains that primarily act in the colon.

Preparation & Dosage

The research provides limited standardized dosage information. L. gasseri SBT2055 was studied at low-to-middle dosages achieving fecal levels of 10⁴ to 10⁶ CFU/g. Viable cells above 10⁶ CFU/g were maintained in yogurt products during 20-day storage. Specific dosage ranges for LG21 are not detailed in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

L. gasseri LG21 pairs strongly with prebiotic fructooligosaccharides (FOS, 3–5g/day) and inulin, which selectively feed Lactobacillus populations, increasing colonization density and extending the bacteriocin-producing activity against H. pylori in the gastric environment. Lactoferrin (200–300mg/day) provides additive synergy by independently chelating iron required for H. pylori virulence while enhancing the strain's immune-stimulating pathway through TLR4 modulation, complementing the interferon-gamma induction already demonstrated by strain 4/13. Zinc carnosine (75mg/day as polaprezinc) works synergistically by repairing gastric mucosal integrity and reducing inflammatory cytokines (TNF-α, IL-8) at the gastric epithelium, creating a less hospitable environment for H. pylori recolonization while supporting the mucosal adhesion sites LG21 relies on — this combination has direct mechanistic overlap in gastric ulcer and gastritis management.

Safety & Interactions

L. gasseri LG21 is generally regarded as safe for healthy adults when consumed in fermented dairy products or capsule form, with no serious adverse events reported in clinical trials to date. Individuals who are immunocompromised, have short bowel syndrome, or carry central venous catheters should exercise caution with any live probiotic due to a theoretical risk of bacteremia or systemic infection. No significant drug interactions have been formally documented, though concurrent use with antibiotics may reduce viable bacterial counts and diminish efficacy; timing supplementation at least two hours from antibiotic doses is commonly advised. Safety data in pregnant and breastfeeding women is insufficient, and use during these periods should be discussed with a healthcare provider.